摘要
由于人类单纯疱疹病毒(herpes simplex virus,HSV)具有原发感染、潜伏感染和复发的感染机制,其发病率呈逐年上升趋势,且目前为止,全球尚无HSV疫苗获批上市,因此,对HSV疫苗的研发迫在眉睫。本文对国内外HSV疫苗的研究进展及其研制过程中可能存在的局限性作一综述。
As the human herpes simplex virus(HSV)has a mechanism of primary infection,latent infection and recurrence infection,its incidence is increasing year by year,and so far,no HSV vaccine has been approved for marketing in the world. Therefore,it is urgent to develop a HSV vaccine. This paper reviews the research progress and possible limitations in development of HSV vaccine at home and abroad.
作者
梁子腾(综述)
黄维金
王佑春(审校)
LIANG Zi-teng;HUANG Wei-jin;WANG You-chun(不详;National Institutes for Food and Drug Control,Key Laboratory of National Health Commission for Research on Quality and Standardization of Biotech Products,Key Laboratory of Biological Product Quality Research and Evaluation of National Medical Products Administration,Beijing 102629,China)
出处
《中国生物制品学杂志》
CAS
CSCD
北大核心
2022年第12期1517-1523,共7页
Chinese Journal of Biologicals
基金
国家科技重大专项(民口)课题任务(2018ZX09101-001)
创新生物技术药评价及标准化关键技术研究(2018-ZX09101001)。
关键词
单纯疱疹病毒
疫苗
局限性
Herpes simplex virus(HSV)
Vaccine
Limitations
